PERSPECTIVE OF INNOVATION DRUG FORMULATION WITH DARUNAVIR ETHANOLAT
Article shows the results of development and technological issues of darunavir ethanolate in capsule form. Soluplus was used to increase the biopharmaceutical characteristics of current drug formulation. Results of dissolution profile studies shows that intensity and release rate of API from the cap...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2019-01-01
|
| Series: | Разработка и регистрация лекарственных средств |
| Subjects: | |
| Online Access: | https://www.pharmjournal.ru/jour/article/view/155 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839586809670008832 |
|---|---|
| author | S. A. Zolotov N. B. Diomina G. F. Vasilenko M. S. Demin |
| author_facet | S. A. Zolotov N. B. Diomina G. F. Vasilenko M. S. Demin |
| author_sort | S. A. Zolotov |
| collection | DOAJ |
| description | Article shows the results of development and technological issues of darunavir ethanolate in capsule form. Soluplus was used to increase the biopharmaceutical characteristics of current drug formulation. Results of dissolution profile studies shows that intensity and release rate of API from the capsules are proportional to concentration of solubilizer and close to comparator agent. Results of the studies have shown necessity to research the physical and chemical characteristics of darunavir ethanolate substances and it could be used in the development of an innovative dosage form. |
| format | Article |
| id | doaj-art-db191dbce96e49758848c3e33f330dda |
| institution | Matheson Library |
| issn | 2305-2066 2658-5049 |
| language | Russian |
| publishDate | 2019-01-01 |
| publisher | LLC Center of Pharmaceutical Analytics (LLC «CPHA») |
| record_format | Article |
| series | Разработка и регистрация лекарственных средств |
| spelling | doaj-art-db191dbce96e49758848c3e33f330dda2025-08-03T19:23:53ZrusLLC Center of Pharmaceutical Analytics (LLC «CPHA»)Разработка и регистрация лекарственных средств2305-20662658-50492019-01-01045660155PERSPECTIVE OF INNOVATION DRUG FORMULATION WITH DARUNAVIR ETHANOLATS. A. Zolotov0N. B. Diomina1G. F. Vasilenko2M. S. Demin3MBA-groupI.M. Sechenov First Moskow State Medical UniversityFederal State Budgetary Institution «Scientific Center for Evaluation of Medicinal Products» of the Ministry of Health of the Russian FederationIMCD RussiaArticle shows the results of development and technological issues of darunavir ethanolate in capsule form. Soluplus was used to increase the biopharmaceutical characteristics of current drug formulation. Results of dissolution profile studies shows that intensity and release rate of API from the capsules are proportional to concentration of solubilizer and close to comparator agent. Results of the studies have shown necessity to research the physical and chemical characteristics of darunavir ethanolate substances and it could be used in the development of an innovative dosage form.https://www.pharmjournal.ru/jour/article/view/155solubilizationdarunаvirincreasing dissolutioncapsules |
| spellingShingle | S. A. Zolotov N. B. Diomina G. F. Vasilenko M. S. Demin PERSPECTIVE OF INNOVATION DRUG FORMULATION WITH DARUNAVIR ETHANOLAT Разработка и регистрация лекарственных средств solubilization darunаvir increasing dissolution capsules |
| title | PERSPECTIVE OF INNOVATION DRUG FORMULATION WITH DARUNAVIR ETHANOLAT |
| title_full | PERSPECTIVE OF INNOVATION DRUG FORMULATION WITH DARUNAVIR ETHANOLAT |
| title_fullStr | PERSPECTIVE OF INNOVATION DRUG FORMULATION WITH DARUNAVIR ETHANOLAT |
| title_full_unstemmed | PERSPECTIVE OF INNOVATION DRUG FORMULATION WITH DARUNAVIR ETHANOLAT |
| title_short | PERSPECTIVE OF INNOVATION DRUG FORMULATION WITH DARUNAVIR ETHANOLAT |
| title_sort | perspective of innovation drug formulation with darunavir ethanolat |
| topic | solubilization darunаvir increasing dissolution capsules |
| url | https://www.pharmjournal.ru/jour/article/view/155 |
| work_keys_str_mv | AT sazolotov perspectiveofinnovationdrugformulationwithdarunavirethanolat AT nbdiomina perspectiveofinnovationdrugformulationwithdarunavirethanolat AT gfvasilenko perspectiveofinnovationdrugformulationwithdarunavirethanolat AT msdemin perspectiveofinnovationdrugformulationwithdarunavirethanolat |